DCGI Provides EUA Approval To SII Manufactured Covovax For 12-17 Year Old

The Drug Controller General of India (DCGI) approved the Serum Institute of India's (SII) Covovax for children between 12-year to 17-year-old. However, the Emergency Use Authorisation came with certain conditions. Previously Covovax was given approval for restricted usage amongst adult. Furthermore, the SII conducted clinical trials on approximately 2,000 children, which shows the efficiency for children against COVID-19 virus, as only COVAXIN (Bharat Biotech) is approved for children.